Kenvue, which has been under increased scrutiny recently after the Trump administration alleged a link between Tylenol and autism, is being acquired by Kimberly-Clark in a multibillion-dollar deal.

According to a Monday press release , Kimberly-Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction that values Kenvue at approximately $48.7 billion.

Just last week, Texas Attorney General Ken Paxton sued Kenvue and its former parent company, Johnson & Johnson.

"We are excited to bring together two iconic companies to create a global health and wellness leader," said Mike Hsu , Kimberly-Clark chairman and chief executive officer.

"We look forward to working with the Kenvue team to bring these companies together and are confident that we

See Full Page